Market For Checkpoint Inhibitor Cancer Treatments Will Reach $16.55bn In 2020, According To New Visiongain Data

13 September 2018
Pharma

A new report by visiongain forecasts the overall world checkpoint inhibitor cancer treatment industry will achieve revenues of $16.55 billion in 2020. Those revenues will expand from 2016 to 2026 as new treatments finish development and reach the market. Those sales predictions and others appear in Checkpoint Inhibitors for Treating Cancer: Market Report with Forecasts 2016-2026, Revealing Potentials of CTLA-4 and PD-1 Inhibitor Drugs and R&D.

That report appears in December 2015. Visiongain is a business intelligence publisher and consultancy in London, UK. It produces research, data and analysis to help organisations understand markets and their potentials.

That survey analyses events, prospects and sales opportunities shaping the development and production of checkpoint inhibitor anti-cancer drug treatments. The work shows multilevel revenue forecasting and qualitative analyses. It also assesses activities of leading companies.

Visiongain’s study predicts expansion in the checkpoint inhibitors market, especially as four new treatments launch. The overall compound annual growth rate for the world market during the forecast period will be 28.4%. In 2014, the CTLA-4 inhibitor submarket formed the most lucrative part of that industry, accounting for 94.2% of the overall world market. However, this segment will shift in market share over the forecast period and lose a large percentage of its market share to the PD-1 inhibitor submarket due to the majority of new treatments joining the market being PD-1 inhibitors.

The checkpoint inhibitors industry has a promising R&D pipeline involving innovative new therapies which are generating a lot of interest, such as LAG-3 inhibitors. Checkpoint inhibitors in development are expected to bring in a new era for immunotherapy and make a difference in long-term success for cancer treatment.

Mashael Zaidi, a pharmaceutical industry analyst in visiongain, said: “The checkpoint inhibitor cancer treatment market got off the ground only in the past few years, but it is expected to continue to rise and change the landscape of cancer treatment. This market has already made strides in melanoma and NSCLC (non-small cell lung cancer) treatment. This trend will continue with further approvals for novel treatments that can offer something new owing to their mechanisms - namely long-term duration of effects.

“Checkpoint inhibitors use the vast potential of the body’s immune response system and its countless connections to attack cancer cells in the body and use the immune memory cells to eliminate relapses. A recurrence of cancer cells in the body could be recognised and wiped out using this method and could leave healthy tissue alone, curbing side effects and increasing the patient benefit-risk ratio. With this kind of potential, many companies have invested in development of checkpoint inhibitors and the pipeline for these treatments is robust and has a promising future.”

Visiongain’s new investigation shows checkpoint inhibitor cancer treatment revenues to 2026 at overall world market, submarket, product and national level.

That study forecasts revenues of the following three subsectors to 2026:

• CTLA-4 Inhibitors
• PD-1 Inhibitors
• Products in development.

That analysis also breaks its overall world revenue forecast to 2026 into three individual forecasts for marketed checkpoint inhibitors for treating cancer:

• Yervoy (ipilimumab, Bristol-Myers Squibb)
• Opdivo (nivolumab, Bristol-Myers Squibb)
• Keytruda (pembrolizumab, Merck)

In addition, that work assesses checkpoint inhibitor R&D in oncology. Profiles appear for 19 drug candidates, with revenue forecasts to 2026 for four drugs:

• Atezolizumab (MPDL3280A, Roche)
• Durvalumab (MEDI4736, AstraZeneca/MedImmune)
• Avelumab (MSB0010718C, Merck KGaA/Pfizer)
• Tremelimumab (CP-675,206, AstraZeneca).

Visiongain’s work also analyses leading national markets for checkpoint inhibitor anti-cancer drugs, providing revenue forecasts to 2026 for these countries:

• The US
• Japan
• Germany, France, the UK, Italy and Spain (EU5)
• The overall EU market
• APAC region, grouped analysis.

That survey examines leading pharmaceutical companies in that field. The investigation also discusses mergers and acquisitions, collaborations and research and development. The work includes interviews with two pharmaceutical companies.

Checkpoint Inhibitors for Treating Cancer: Market Report with Forecasts 2016-2026, Revealing Potentials of CTLA-4 and PD-1 Inhibitor Drugs and R&D adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostics and outsourced services, including contract research, manufacturing and selling.

Recent News

“Global Asthma & COPD Therapies market set to grow to $46bn by 2024” says new Visiongain report

ecent studies and expert opinion suggest that the asthma and COPD market is more segregated than previously believed.

19 March 2019

Read

“Global Anaesthesia Drugs market set to grow to $11.8bn by 2024” says new Visiongain report

The intravenous route is the most commonly used route of administration owing to its high effectiveness during critical surgeries, its high adoption in hospitals, and availability of advanced intravenous drugs which cater the need of surgeons.

19 March 2019

Read

“The Global Pharma Contract Sales market will be driven by cost saving and the need for more flexibility” says new Visiongain report

With higher-cost therapies in development, combined with increasing burdens on healthcare budgets from ageing populations and rising disease incidence, market access is becoming more challenging in countries worldwide.

28 February 2019

Read

“Drug Delivery Technologies market set to grow to $355bn by 2024” says new Visiongain report

The potential use of drug delivery technologies in product lifecycle management and the enhancement of drug efficacy in many therapeutic sectors will act as drivers for growth of the market over the coming decade.

28 February 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1